Nakumpleto ng Vertex ang rolling BLA submission para sa povetacicept sa IgAN

Nakumpleto ng Vertex ang rolling BLA submission nito sa FDA para sa povetacicept sa IgA nephropathy para sa accelerated approval, kasunod ng positibong Phase 3 interim analysis data. Gumagamit ang kumpanya ng Priority Review Voucher, na inaasahang magpapabilis sa FDA review sa anim na buwan mula sa petsa ng BLA acceptance. Ang submission na ito ay nagpapabilis sa povetacicept patungo sa potensyal na U.S. market entry sa IgAN.

Mahahalagang fact

Na-file: May 4, 2026, 08:05 PM
Kaganapan: Naisumite ang aplikasyon
Direksyon: Positibo
Kumpanya: VRTXVertex Pharmaceuticals
Asset: povetacicept
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

EX-99.1 2 ex-991_q12026.htm EX-99.1 Document Vertex Reports First Quarter 2026 Financial Results — Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 — — Povetacicept program continues rapid advancement: Completed rolling BLA submission for U.S. accelerated approval for povetacicept in IgA nephropathy, following positive Phase 3 interim analysis data; initiated Phase 3 portion of Phase 2/3 study in primary membranous nephropathy and Phase 2 proof-of-concept study in generalized myasthenia gravis— — Continued progress across broad clinical-stage pipeline, including label expansion of eligible U.S. patient populations for ALYFTREK and TRIKAFTA and completion of U.S. regulatory submission for approval of CASGEVY in children ages 5 to less than 12 years old with SC

SEC 8-K